Chair: Weng-Onn Lui (Stockholm, Sweden)

09:30-10:00 David Schrama (Würzburg, Germany)
Impairing T-antigen expression in MCPyV-positive Merkel cell carcinoma cells

10:00-10:30    Axel Zur Hausen (Maastricht, Netherlands)
Constitutive early B cell differentiation in Merkel cell carcinoma and its implications  for cellular identity

10:30-11:00    Mahtab Samimi (Tours, France)
Outcomes of Merkel Cell Carcinoma patients with metastatic and recurring disease in France

11:00-11:15    Wen Xu (Brisbane, Australia)
IMAT (Immunotherapy Merkel Adjuvant Trial) - Trial in Progress - A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma

11:15-11:45    Coffee break   

11:45-12:15    Paul Nghiem (Seattle, USA)
A single postoperative dose of radiotherapy (8 Gy) has comparable efficacy to a standard 5-week course for localized Merkel cell carcinoma

12:15-1230     Nalini Srinivas (Heidelberg, Germany)
Tertiary Lymphoid Structures in Merkel Cell Carcinoma Enable the Infiltration of Naïve and Central Memory T-Cells with a Diverse T-Cell Receptor Repertoire Associated with Response to Immunotherapy

12:30-12:45    Anja Lange (Essen, Germany)
Whole genome sequencing analysis of MCC cell lines - The hidden information in short-read whole genome sequencing data and the challenge to uncover them

12:45-13:30    Lunch                

Chair: John Paoli (Gothenburg, Sweden)

13:30-14:00    Kasia Korecka (Poznan, Poland)
Dermoscopy in Merkel cell carcinoma

14:00-14:30    Masahiro Shuda (Pittsburgh, USA)
Role of CBP/p300 histone acetyltransferase in virus-induced Merkel cell carcinogenesis

14:30-14:45    Tom Andrew (Newcastle, UK)
Merkel cell carcinoma – From DeepMerkel to crystal clear

14:45-15:00    Nicole Fischer, Jürgen Becker, John Paoli & Weng-Onn Lui
Final remarks